Baird Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $33
Portfolio Pulse from jenniferd'souza@benzinga.com
Baird analyst Jeff Johnson has maintained a Neutral rating on Tandem Diabetes Care (NASDAQ:TNDM) and lowered the price target from $38 to $33.
August 04, 2023 | 3:26 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Baird has maintained a Neutral rating on Tandem Diabetes Care and lowered the price target from $38 to $33.
The lowering of the price target by Baird from $38 to $33 indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on Tandem Diabetes Care's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100